Drug intelligence / Profile preview

[18F]AlF-FAPI-74

Development stage
Unknown
Lead developer
SOFIE
Modality
Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

[18F]AlF-FAPI-74 is a radiopharmaceutical diagnostic imaging agent used in positron emission tomography (PET) imaging. It is a fibroblast activation protein (FAP) inhibitor (FAPI) labeled with fluorine-18 via an aluminum fluoride ([18F]AlF) complex. FAP is a cell-surface serine protease that is highly expressed in the cancer-associated fibroblasts (CAFs) of the tumor stroma in various epithelial cancers, including gastric and esophagogastric junction adenocarcinomas, while showing low expression in normal tissues. This high tumor-to-background ratio makes it an effective tool for staging and detecting primary tumors and metastases. The tracer was developed to overcome the logistical limitations of Gallium-68 labeled tracers by utilizing the longer half-life and large-scale production capabilities of Fluorine-18. It is currently being evaluated in the PLASTIC-3 trial to assess its impact on the staging of advanced gastric cancer compared to standard laparoscopy.

Other names
[18F]AlF-labeled FAPI-7418F-AlF-FAPI-74
02

Targets

FAP (Fibroblast activation protein alpha)

Beyond the preview

Go deeper on [18F]AlF-FAPI-74.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on [18F]AlF-FAPI-74.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call